Literature DB >> 26114697

Biological agents: what they are, how they affect oral health and how they can modulate oral healthcare.

E Georgakopoulou1, C Scully2.   

Abstract

Biological agents - biologics, biologicals or biopharmaceuticals - are any medicinal product manufactured in, or extracted from, a biological source. They are often generated by DNA recombinant biotechnology and several dozen therapeutic monoclonal antibodies (mAbs) are now marketed for a variety of indications, increasingly in the management of inflammatory immune-mediated disorders, transplantation rejection and cancer treatments. Immunomodulatory mAbs are expensive, must be given by injection or infusion and can have adverse effects but are increasingly used and can be highly effective agents. This paper reviews these agents and their increasing relevance to oral science and healthcare.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26114697     DOI: 10.1038/sj.bdj.2015.439

Source DB:  PubMed          Journal:  Br Dent J        ISSN: 0007-0610            Impact factor:   1.626


  88 in total

1.  Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept.

Authors:  Christopher Sacher; Andrea Rubbert; Cathrin König; Karin Scharffetter-Kochanek; Thomas Krieg; Nicolas Hunzelmann
Journal:  J Am Acad Dermatol       Date:  2002-01       Impact factor: 11.527

Review 2.  Review: nomenclature and biologic significance of cytokines involved in inflammation and the host immune response.

Authors:  W C Liles; W C Van Voorhis
Journal:  J Infect Dis       Date:  1995-12       Impact factor: 5.226

Review 3.  Orofacial adverse effects of biological agents.

Authors:  Eleni A Georgakopoulou; Crispian Scully
Journal:  J Investig Clin Dent       Date:  2014-05-22

4.  Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.

Authors:  Valentina Guarneri; David Miles; Nicholas Robert; Véronique Diéras; John Glaspy; Ian Smith; Christoph Thomssen; Laura Biganzoli; Tanya Taran; PierFranco Conte
Journal:  Breast Cancer Res Treat       Date:  2010-04-02       Impact factor: 4.872

Review 5.  The European Medicines Agency Review of Pertuzumab for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer: summary of the scientific assessment of the committee for medicinal products for human use.

Authors:  Hector Boix-Perales; Jeanett Borregaard; Kristina Bech Jensen; Jens Ersbøll; Sara Galluzzo; Rosa Giuliani; Cinzia Ciceroni; Daniela Melchiorri; Tomas Salmonson; Jonas Bergh; Jan H Schellens; Francesco Pignatti
Journal:  Oncologist       Date:  2014-06-13

6.  New-onset heart failure in association with severe hypertension during trastuzumab therapy.

Authors:  Joerg Herrmann; Sandra M Herrmann; Tufia C Haddad
Journal:  Mayo Clin Proc       Date:  2014-11-01       Impact factor: 7.616

Review 7.  Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.

Authors:  Xiaolei Zhu; Shenhong Wu; William L Dahut; Chirag R Parikh
Journal:  Am J Kidney Dis       Date:  2007-02       Impact factor: 8.860

8.  Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

Authors:  N Mohan; E T Edwards; T R Cupps; P J Oliverio; G Sandberg; H Crayton; J R Richert; J N Siegel
Journal:  Arthritis Rheum       Date:  2001-12

9.  Adalimumab in the management of cutaneous and oral lichen planus.

Authors:  Tomas J Chao
Journal:  Cutis       Date:  2009-12

Review 10.  Rilonacept in the treatment of chronic inflammatory disorders.

Authors:  Michael F McDermott
Journal:  Drugs Today (Barc)       Date:  2009-06       Impact factor: 2.245

View more
  2 in total

1.  Increasing collaboration between GPs and dental practitioners.

Authors:  Holly Boyes
Journal:  Br J Gen Pract       Date:  2015-09       Impact factor: 5.386

2.  Anti-thrombotic agents.

Authors:  C Scully; N A Robinson
Journal:  Br Dent J       Date:  2015-12       Impact factor: 1.626

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.